Cftr Trikafta denied as non-formulary by Humana?

Humana's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Trikafta as Non-Formulary

A non-formulary denial means Trikafta (elexacaftor/tezacaftor/ivacaftor) is not included on your specific Humana plan's drug list, or it is listed at a tier that requires additional authorization before coverage applies. Formulary placement varies by plan year and by the specific Humana product you are enrolled in — it is not a universal Humana-wide decision. The denial does not mean Trikafta is categorically unavailable; it means you must pursue a formulary exception or an exception to the non-formulary exclusion on medical-necessity grounds.

## Why It Is Appealable

Federal law requires plans offering prescription drug coverage to have an exceptions process for non-formulary drugs when there is no medically appropriate formulary alternative. For cystic fibrosis patients with specific CFTR mutations, the argument that a formulary alternative is therapeutically equivalent is often weak, because modulator selection is genotype-driven. Your prescriber can document that no formulary drug addresses your mutation class equivalently.

## Federal Appeal Framework

• Formulary exception request (parallel track): File a formulary exception simultaneously with your formal appeal. Humana must respond within 72 hours for standard exceptions and 24 hours for urgent cases. This is often the fastest path to coverage.
• Internal appeal (Level 1): File within the deadline on your EOB — typically within 60 to 180 days of the denial notice depending on your plan type. Humana must respond within 30 days (non-urgent) or 72 hours (urgent).
• External review (ACA §2719 / ERISA §503): After exhausting internal remedies, you have approximately 4 months to request an IRO review. External reviewers can override non-formulary exclusions when the clinical evidence supports it.

## Documentation to Gather

1. Humana formulary — download the current formulary for your specific plan; identify what CF therapies, if any, are listed as formulary alternatives. 2. CFTR genotype report — certified lab confirming your mutation type; used to show that formulary alternatives (if any) are not indicated for your genotype. 3. Prescriber medical-necessity letter — your CF specialist should state that no formulary alternative is clinically appropriate for your specific mutation class, reference the FDA-approved prescribing label for both Trikafta and any listed alternative, and explain the clinical risk of using a non-indicated therapy. 4. FDA prescribing labels — for Trikafta and any Humana-listed formulary CF drug, to document the distinct approved indications. 5. Clinical notes — diagnosis confirmation, mutation report, disease burden documentation, and any prior experience with formulary alternatives if they were tried.

## Criteria-Mapping Structure

| Non-Formulary Exception Requirement | Supporting Evidence | |---|---| | Formulary alternative exists | Humana formulary printout listing alternative(s) | | Alternative is not clinically appropriate | Prescriber letter + FDA label comparison showing distinct indications | | Medical necessity of Trikafta specifically | Specialist letter documenting genotype-driven clinical need |

## Practical Tip

Check whether your plan year is ending soon. Formulary lists change annually, and Trikafta's formulary status may differ in the next plan year. If you are near open enrollment, ask Humana's pharmacy team whether a plan option with Trikafta on formulary is available to you.